Corona vaccine race continues • Preliminary results of the joint trial of the pharmaceutical company AstraZenka and the University of London showed encouraging results among older vaccinators • There is no agreement between the State of Israel and AstraZenka, but negotiations are underway to receive vaccine doses • All details
The race for the vaccine continues
Photography:
AFP - Archive
Good news from the UK:
Preliminary results from the second phase of an experiment by Oxford University and the pharmaceutical company AstraZeneca published this morning (Thursday) show that the vaccine produces a strong immune response in adults.
Archive photo: GPO
Despite the joy of the report, it should be noted that similar to the case of a modern company - the State of Israel has not signed an agreement with the pharmaceutical company and negotiations are underway on the issue.
The trial involved 560 healthy volunteers who received two doses of vaccine or placebo, and according to the publication in the medical journal Lancet, indicate that people aged 70 and over, who are considered a risk group, can develop immunity to the virus.
"The strong responses of antibody and T cell development observed in adults who took part in the study are very encouraging," said Mahshai Ramasmi, a lead researcher on Oxford's research team.
"We hope this means our vaccine will help keep people who are part of the risk groups in the population, but we need to continue researching the issue so we can ensure certainty."
Additional researchers added that trials in the third trial continue to be performed on people in good health, in order to test the effectiveness of the vaccine in a wide range of people, which will be published in the coming weeks.
As you may recall, according to the announcement by the Pfizer and Modern companies about the effectiveness of the vaccine they have developed, the joint trial of Oxford and AstraZeneca is considered one of the leaders in the global race to develop a vaccine for the corona virus.
But unlike the vaccine developed by the drug companies, the experiment in question uses a vaccine that uses a weakened version of the flu found in chimpanzees.
